We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| AstraZeneca PLC | NYSE:AZN | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 54.17 | 0 | 01:00:00 |
From May 2019 to May 2024
By Carlo Martuscelli
Hutchison China MediTech Ltd. (HCM.LN) and AstraZeneca PLC (AZN.LN) said jointly Tuesday that the drug savolitinib administered in conjunction with other drugs showed preliminary antitumor activity based on preliminary results of two clinical trials.
China MediTech discovered savolitinib and is developing the drug in cooperation with AstraZeneca. The two studies examined how the drug interacts with osimertinib and gefitinib--drugs trademarked by AstraZeneca--in the treatment of lung cancer.
More specifically, the studies observed how the drugs interacted with patients' epidermal growth factor receptor mutation-positive non-small cell lung cancer.
The results were presented at the World Conference on Lung Cancer in Yokohama, Japan.
Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com
(END) Dow Jones Newswires
October 17, 2017 05:08 ET (09:08 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
